Roche (RHHBY) announced collaborations with Ibex Medical Analytics and Amazon (AMZN) Web Services, enabling pathology laboratories to access Ibex’s AI-powered decision support tools to support clinicians in breast and prostate cancer diagnosis through the navify Digital Pathology software platform. Digital pathology refers to the digitalization of the traditional pathology workflow starting from slide scanning to visualization to analysis. Digital pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and providing an opportunity for collaboration in pathology workflows. The integrated artificial intelligence-based tools can be applied to help enhance clinical decision support, improve productivity and shorten turnaround time in pathology laboratories.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
- Immunovant price target raised to $57 from $28 at Piper Sandler
- Roivant (NASDAQ:ROIV) Gains after Roche’s $7.1 Billion Buy of Televant
- Roche to acquire Telavant from Roivant Sciences for $7.1B upfront
- [Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant